VERU experienced a severe financial deterioration with revenue collapsing 58.6% from $39.4M to $16.3M while operating cash flow worsened to -$30.0M, accompanied by a 50.6% decline in total assets.
The dramatic revenue decline combined with worsening cash burn signals potential business model distress for this late-stage biopharmaceutical company. The company's financial runway appears to be shrinking rapidly, with total assets cut in half and stockholders' equity declining 43.3%, raising questions about funding needs for continued operations.
VERU's financial position deteriorated significantly across all key metrics, with revenue plummeting 58.6% and operating cash flow worsening by $8.3M to -$30.0M. The balance sheet contracted substantially with total assets falling 50.6% and liabilities decreasing 59.1%, while stockholders' equity dropped 43.3%. Despite the lower asset base and reduced interest expense, the company's core operating performance weakened considerably, though net losses improved slightly due to the reduced scale of operations and lower financing costs.
Buyback activity reduced 99.9% — capital being redeployed elsewhere or cash conservation underway.
Capex reduced 99.3% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 59.1% — deleveraging improves balance sheet strength and financial flexibility.
Revenue declined 58.6% — significant demand weakness or market share loss warrants investigation.
Total assets contracted 50.6% — asset sales, write-downs, or balance sheet optimization underway.
Current assets declined 46.3% — monitor working capital adequacy and short-term liquidity.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Net income grew 39.9% — bottom-line growth signals improving overall business health.
Operating cash flow fell 38.6% — earnings quality concerns; investigate working capital changes and non-cash items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →